Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02019355 · ClinicalTrials.gov registry record · Early Phase 1

Actinic Keratosis Study

A Early Phase 1 study of Actinic Keratosis, sponsored by Washington University School of Medicine.

Completed
Registry status
Early Phase 1
Development phase
132
Enrollment target
1
Study location

NCT02019355 is a Early Phase 1 study of Actinic Keratosis that has completed, run by Washington University School of Medicine. The registered enrollment target is 132 participants, below the 181-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02019355, a Early Phase 1 study of Actinic Keratosis, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Early Phase 1
Development phase
132 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to determine the effectiveness of a new combination therapy for actinic keratosis. This study investigates a new indication for an FDA-approved topical medication, calcipotriol, for treatment of actinic keratosis, including how well it works and how safe it is when used in combination with the standard of care medication (5-fluorouracil) for the skin condition.

Conditions Studied

Interventions

  • DRUG Vaseline
  • DRUG 5-fluorouracil 5% cream
  • DRUG Calcipotriol 0.005% ointment

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2013-10
Est. Completion 2015-03
Phase Early Phase 1

What the Registry Record Tells You About NCT02019355

The ClinicalTrials.gov registry entry for NCT02019355 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (27% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Actinic Keratosis appearing as the primary indexed condition, and to 3 interventions - of which Vaseline is the first listed.

NCT02019355 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT02019355 about?

NCT02019355 is a clinical study titled "Actinic Keratosis Study". The main purpose of this study is to determine the effectiveness of a new combination therapy for actinic keratosis. This study investigates a new indication for an FDA-approved topical medication, calcipotriol, for treatment of actinic keratosis, including how well it works and how safe it is when ...

What is the current status of trial NCT02019355?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 132 participants. The study started on 2013-10. Estimated completion is 2015-03.

What conditions does trial NCT02019355 study?

This clinical trial studies the following conditions: Actinic Keratosis.

What interventions are being tested in trial NCT02019355?

The interventions under investigation include: Vaseline (DRUG), 5-fluorouracil 5% cream (DRUG), Calcipotriol 0.005% ointment (DRUG).

Who is sponsoring clinical trial NCT02019355?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02019355 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Actinic Keratosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.